Metrics to compare | ORKA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipORKAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −44.4x | −3.2x | −0.5x | |
PEG Ratio | −0.79 | −0.05 | 0.00 | |
Price/Book | 8.0x | 3.7x | 2.6x | |
Price / LTM Sales | - | 197.2x | 3.3x | |
Upside (Analyst Target) | 126.1% | 96.4% | 47.7% | |
Fair Value Upside | Unlock | 1.6% | 6.6% | Unlock |
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.